Description: Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. The company is developing molecular diagnostics tests to identify molecules or immunobiomarkers for Alzheimer's disease, non-small cell lung cancer, and pancreatic cancer, and other cancers; point-of-care diagnostic tests to detect prostate specific antigen; and laboratory developed tests comprising 4Kscore test for the detection of prostate cancer. It also operates OURLab, a full-service medical laboratory specializing in urologic pathology. In addition, the company is developing CTAP101 Capsules to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; and Fermagate Tablets to treat hyperphosphatemia in end-stage renal disease patients on chronic hemodialysis. Further, it is developing oligonucleotide therapeutics, which are under pre-clinical studies for the treatment of various illnesses, such as cancer, heart disease, metabolic disorders, and genetic anomalies; heparin-derived oligosaccharide for asthma and chronic obstructive pulmonary diseases; influenza vaccines; alpha-galactosyl ceramide analogs for cancer, infectious disease, and autoimmune disease; and rolapitant, a NK-1 candidate that has completed Phase II clinical testing for the prevention of chemotherapy induced nausea and vomiting. Additionally, the company develops and produces specialty active pharmaceutical ingredients; offers ophthalmic and other pharmaceutical products; and provides cardiovascular products, vaccines, antibiotics, gastro-intestinal products, and hormones. It operates in the United States, Chile, Mexico, Israel, and Spain. OPKO Health, Inc. is based in Miami, Florida.
Home Page: www.opko.com
OPK Technical Analysis
4400 Biscayne Boulevard
Miami,
FL
33137
United States
Phone:
305 575 4100
Officers
Name | Title |
---|---|
Dr. Phillip Frost Ph.D. | Chairman & CEO |
Dr. Jane H. Hsiao M.B.A., MBA, Ph.D. | Vice Chairman & Chief Technical Officer |
Mr. Adam E. Logal | Sr. VP, CFO, Chief Accounting Officer & Treasurer |
Mr. Steven D. Rubin Esq., J.D. | Exec. VP of Admin. & Director |
Dr. Jon R. Cohen M.D. | Advisor |
Dr. Elias Adam Zerhouni M.D. | Pres & Vice Chairman |
Dr. Arie Gutman | Pres of API |
Mr. James DeMarco | Sr. VP of Pharmaceutical Sales |
Dr. Akhtar Ashfaq | Sr. VP of Clinical R&D and Medical Affairs |
Ms. Jane Pine Wood Esq., J.D. | Chief Legal Officer of Bio-Reference Laboratories |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 64.5161 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 0.6119 |
Price-to-Sales TTM: | 0.7916 |
IPO Date: | 1995-11-02 |
Fiscal Year End: | December |
Full Time Employees: | 5767 |